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1. Introduction
Bio-medical prevention of sexually transmitted HIV infection is an evolving area in the field
of HIV. In recent years, multiple studies have demonstrated the efficacy of diverse biomedical
interventions to prevent the sexual acquisition of HIV infection in specific populations. The
major developments in the field of prevention of sexual transmission of HIV include male
circumcision, HIV viral suppression of HIV infected individuals (Treatment of positives), use
of antiretrovirals before exposure to HIV (Pre-exposure prophylaxis), and use of microbicides.
Some of these highly controlled studies demonstrated high levels of protection ranging from
55 to more than 90% when a single intervention has been studied. However, in real world
situations, it is foreseeable that individuals will have the opportunity and option to choose,
and ideally to combine, appropriate interventions according to their background, attitudes,
preferences and availability of methods.
Male circumcision: Male circumcision effectively decreases rates of heterosexual transmission
of HIV: There is now ample scientific evidence that male circumcision reduces the risk of
acquiring HIV through heterosexual intercourse in males by approximately 51 to 60%, thus
exceeding the 30 percent risk reduction set as a target for an AIDS vaccine. This level of
protection is similar to the 67.5% relative reduction in the risk of maternal-infant transmission
of HIV with the use of zidovudine in HIV infected pregnant women; currently one of the most
successful strategies to prevent HIV infection in a selected population, newborns. The evidence
of the effectiveness of male circumcision in decreasing the risk of HIV infection in males is so
compelling that in March 2007, the World Health Organization and the Joint United Nations
Programme on HIV/AIDS held a technical consultation on male circumcision and produced a
document that stated that male circumcision should be recognized as an efficacious interven‐
tion for the prevention of heterosexually acquired HIV infection in men. Male circumcision
(MC) has been proven to be a potent HIV prevention strategy, reducing risk of HIV acquisition
in heterosexual men by 50-60%. One of the most successful interventions to prevent the
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acquisition of HIV infection in heterosexual men is circumcision, which has reduced HIV risk
by 50-60% among heterosexual men in sub-Saharan Africa. The uptake of male circumcision
in traditionally non-circumcision communities have been varied and influenced by different
factor. In the US males from racial and ethnic minorities are less likely to be circumcised and
also more likely to become infected with HIV so a recently published analyses showed that
newborn circumcision resulted in lower expected HIV-related treatment costs and a slight
increase in quality-adjusted life years.
Treatment of Positives: Since the early years of the epidemic, it was demonstrated that the use
of antiretrovirals in infected pregnant women decreased the likelihood of HIV infection in the
new born. Additional studies demonstrated that the key factor in the transmission of the
infection from the mother to the newborn was the maternal HIV viral load; and then the
suppression of HIV by the administration of antiretrovirals became the standard of care in the
management of HIV infected pregnant women. This practice led to the almost eradication of
congenital HIV infection in communities with access to medications. Circumstantial evidence
suggested that the same principle could be applied to the sexual transmission of HIV as in
general there is correlation between the HIV viral load in blood and genital secretions. In 2011
a breakthrough study proved that treatment of HIV positive decreased the likelihood of sexual
transmission in more than 96% in discordant heterosexual couples.
Pre-exposure prophylaxis (PrEP) in MSM and heterosexual men and women: PrEP involves
the use of antiretroviral medications before potential HIV exposure to prevent infection. In
recent years several studies suggested the possible efficacy of the use of TDF/FTC as PrEP; but
in the last six months, several controlled studies have provided definitive proof of its efficacy
in certain populations: iPrEx was a study that randomized 2499 HIV-negative MSM or
transgender women who have sex with men to take oral daily tenofovir and emtricitabine
(FTC/TDF) or placebo. Overall, 100 subjects became infected during the study (36 in the FTC/
TDF group and 64 in the placebo group), indicating a 44% reduction in the HIV incidence. The
Partners PrEP Study was a phase III, randomized, double blind, placebo-controlled, three arm
trial of oral daily (FTC/TDF) PrEP for the prevention of HIV acquisition by HIV seronegative
partner in HIV serodiscordant partnerships. The independent DSMB recommended that the
results of the study be publically reported, nearly 2 years earlier than expected, and the placebo
arm discontinued, because clear demonstration of HIV protection due to PrEP. The TDF2A
was a double-blind, randomized, trial of daily oral FTC/TDF or placebo for prevention of HIV
acquisition in young (18-39) women and men in Bostwana. A total of 1219 individuals were
randomized, about 30% of the study population did not complete follow up. Adherence to
PrEP overall was estimated to be approximately 84%. Overall 9 HIV infections occurred among
those assigned to FTC/TDF compared to 24 among those assigned to placebo, translating to
an efficacy for HIV protection of 63%. All these studies shown that PrEP is a viable biomedical
intervention that can be use for the prevention of sexually transmitted HIV infection in both
heterosexual and male who have sex with men populations but is highly dependent of the
adherence to the medications. There are few promising agents that could be use over extended
periods of time decreasing the need for daily medication.
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Microbicides: Given the theoretical advantages of a microbicide (controlled by women, no
need for male cooperation) the search for an effective product was elusive until investigators
from CAPRISA 004 study reported at the World AIDS conference in 2010 in Vienna, that 1%
tenofovir gel used with coitus reduced HIV risk by 39% among 889 South African women.
Sub-analyses of the data showed that protection was more pronounced (54%) in women with
higher adherence to the gel. Several studies are under way with other products and with
alternative delivery systems that will alleviate the need for strict adherence to its use before
and after sex.
2. Bio-medical interventions to prevent hiv sexually transmitted infection
2.1. Male circumcision
Male circumcision is the surgical procedure that consists in the removal of some or all the
foreskin of the penis [1]. The word “circumcision” comes from the Latin circum (meaning
“around”) and caedere (meaning “to cut”) [2]. The foreskin is a continuation of the skin from
the shaft of the penis, which covers the glans penis and the urethral meatus. The foreskin is
attached to the glans by the frenulum, a highly vascularized tissue of the penis. Male circum‐
cision is one of the oldest surgical procedures known, traditionally undertaken as a mark of
cultural identity or religious importance [3]. Rates of male circumcision are different around
the word and related to cultural and religious beliefs [4]. Historically, male circumcision has
been associated with religious practice and ethnic identity. Circumcision was practiced among
ancient Semitic peoples including Egyptians and Jews, with the earliest records depicting the
practice coming from Egyptian tomb artwork (from the Sixth Dynasty, 2345-2181 B.C.) and
wall paintings dating from around 2300 BC [3]. Muslims are the largest religious group to
practice male circumcision. As an Abrahamic faith, Muslims practice circumcision, as a
confirmation of their relationship with God, and the practice is also known as tahera, meaning
purification [3]. With the global spread of Islam from the 7th century AD, circumcision was
widely adopted among previously non-circumcising peoples. In some regions, male circum‐
cision was already a cultural tradition prior to the arrival of Islam (for example among the
Poro in West Africa, and in Timor in SE Asia). [5-7] Circumcision has also been practice for
non-religious reasons for many thousand of years in sub-Saharan Africa, and in many ethnic
groups around the world, including aboriginal Australasians, the Aztecs and Mayans in the
Americas, inhabitants of the Philippines and eastern Indonesia and various pacific Islands,
including Fiji and the Polynesian islands [3]. In the majority of these cultures, circumcision is
an integral part of a rite of passage to manhood, although originally it may have been a test of
bravery and endurance. Male circumcision traditionally has been done for medical and non
medical reasons (including religious or cultural reasons). When it is practiced for non-medical
reasons it is typically performed in the neonatal period or just before the adolescence. The
practice of circumcision, in particular of neonatal circumcision remains highly controversial
despite recent evidence of the medical benefits, including decreased risk of heterosexual
acquisition of HIV infection by men, decreased risk of acquisition of several sexually trans‐
mitted infections, decreased risk of urinary tract infection and recent evidence of decreased
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risk of prostate cancer [8-10]. There are no reliable data of the rate of circumcision in many
areas of the world in particular in regions where is not commonly practiced; but in general it
is believed that rates of circumcision are very low in Latin-America including the Caribbean
region, China, India and Europe [2], Fig 1.
Global map of male circumcision prevalence at country level, as of December 2006.
Figure 1. Worldwide prevalence of Male Circumcision.
2.1.1. Studies addressing MC in the field of HIV prevention
2.1.1.1. Cohort studies
The first paper suggesting a protective effect of MC against HIV infection was published in
1986 [11]. Since then, many observational studies have been published, some of which have
observed that most men living in East and southern Africa, the regions with the highest
prevalence of HIV are not circumcised [12-14]. More than 30 cross-sectional studies found the
prevalence of HIV to be significantly higher in uncircumcised men than in those who are
circumcised [15] and 14 prospective studies all showed a protective effect, ranging from 48%
to 88% [16-18]. A systematic review and meta analyses of studies from sub-Saharan Africa
reported an adjusted relative risk of 042 (95% CI 0.34-0.54) in all circumcised men, with a
stronger adjusted relative risk of 0.29 (0.20 – 0.41) in circumcised men who were at higher risk
of acquiring HIV [19].
2.1.1.2. Randomized studies
Given the compelling observational data of the potential protective role of male circumcision
in the acquisition of heterosexually transmitted HIV infection and the growing crisis of HIV
infection in sub-Saharan Africa; it was clear that only randomized studies could provide
unequivocally evidence of this protection. Under the sponsorship of the National Institutes of
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Health (NIH) and the ARNS (French National Research Agency), three independent but
similar randomized control trials were launched in three different communities in South Africa
in 2002-2003 to address this question. The studies were performed in South Africa, Kenya, and
Uganda, within peri-urban, urban, and rural communities respectively [20-22]. The study
conducted in South Africa (Orange farm, bordering Johannesburg) included 3,128 men 18 to
24 years old. Eligible men were randomly allocated to undergo immediate or delayed (offered
at the end of the follow up period) circumcision. Men were assessed at 3, 12 and 24 months for
HIV acquisition, sexually transmitted infections, and changes in sexual behaviors. Interim
analysis in 2004 revealed a 0.4 relative risk of HIV acquisition (95% CI, 0.24%-0.68%.; P < 0.001)
among the circumcised compared to uncircumcised participants. This finding corresponds to
a protective effect of circumcision of 60%, which is a level of protection similar many used
vaccines. Given these striking results, the safety and monitoring board discontinued the trial
early, and circumcision was offered to the control arm. The Orange Farm study results
prompted ethical concerns about continuation of the two remaining studies. The World Health
Organization (WHO) recommended continuation but mandated a previously unplanned,
earlier interim evaluation. At the interim evaluation, the studies in Kenya and Uganda
provided evidence of protection against HIV infection of 50% to 60%, remarkably similar to
the results from the Orange Farm trial. These two trials were discontinued prematurely on
December 12, 2006. Together, the three studies demonstrated a 50% to 60% reduction in HIV
acquisition by medicalized circumcision. [20-22] In total, 10,908 uncircumcised, HIV-negative
adult men were randomly assigned to intervention or control arms, and followed for up to 2
years. Overall retention rates were high (86-92% at the end of follow up, when men in the
control arm were offered circumcision). Recent findings support the long-term benefit
conveyed by MC, with the Kisumu, Kenya cohort maintaining/modestly increasing the earlier
level of protection (60% to 64%) at 54 month follow up [23]. These studies, among others,
provide “unequivocal evidence that circumcision plays a causal role in reducing the risk of
HIV infection among men” [24].
On the basis of the findings from the three clinical trials, a WHO and UNAIDS consultation in
March 2007, recommended that circumcision should be recognized as an effective intervention
for HIV prevention of heterosexual HIV acquisition in men [24]. WHO and UNAIDS also
recommended that male circumcision should be offered HIV-negative men in addition, but
not as a substitute, to other HIV risk-reduction strategies. The public-health effect of male
circumcision will be largest in generalized epidemics. As such, WHO and UNAIDS recom‐
mend that countries with hyperendemic and generalized epidemics and low prevalence of
male circumcision expand access to safe male circumcision services within the context of
ensuring universal access to comprehensive HIV prevention, treatment, care, and support. [25]
2.2. Acceptability of MC as a tool for HIV prevention
The public health benefit of MC as a tool for HIV prevention, will depend of many factors. One
of the most important is the acceptability and uptake of circumcision in traditionally non-
circumcising societies. It can be expected that the benefit can spread beyond circumcised men
because if sufficient number of males are circumcised, circumcision in the long range will also
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protect women; effect similar to herd immunity [26]. In addition to the proportion of males
who will become circumcised, the age at circumcision will be also a determinant of how rapidly
the intervention results in reduction of HIV prevalence in the population. For example, if boys
and young men before sexual debut are targeted, the measurable impact it is not likely to be
realized for over 10 years; if older boys and men up to 30 years are prioritized a more rapid
effect can be expected. On the other hand, circumcision of neonates, in whom the procedure
is simpler and less risky, the impact of the strategy on HIV incidence would not be expected
for at least 20 years. [25] Because acceptance of male circumcision by men and by parents of
males in traditionally non-circumcising communities will be crucial to the success of a MC
intervention for reducing HIV prevalence a significant number of studies have been conducted
in different non-circumcising communities with high or increasing rates of HIV infection
across the globe [26-29]. Across most of these studies, the most common barriers to the
acceptability of male circumcision include the following factors: pain (apprehension about
pain during and after the procedure has been reported to be the major barrier to MC accept‐
ability; culture and religion have also factors that have been consistently brought up in the
discussions about acceptability of MC in diverse groups; cost of the procedure has been named
as a significant barrier to MC acceptability and safety (potential for complications and adverse
effects). Other potential barriers named in some but not in all studies include: lack of access to
health care, required time away from work, the concern about loss of penile sensitivity,
reduction in penis size, decreased ability to satisfy women, excessive sexual desire, increased
promiscuity and the perception of circumcision as old-fashioned [28-29]. On the other hand,
the most consistently named facilitators of MC include the following factors: hygiene, which
has universally been recognized as a major benefit of MC; protection from sexually transmitted
diseases and HIV (linked through hygiene) and improved sexual pleasure.
In summary, the protective effect of adult male circumcision on HIV acquisition has been
reported in a review of epidemiological studies and demonstrated by three randomized
controlled trials conducted in Southern and Eastern Africa, which found that the risk of HIV
acquisition among circumcised men was reduced by about 60%. Based on this evidence, in
2007 WHO/UNAIDS recommended adult male circumcision as an important, additional
intervention which should be delivered as part of a comprehensive HIV prevention package
in communities with generalized HIV epidemics and low male circumcision rates. Since then,
a number of initiatives have taken place in different countries to role out adult male circum‐
cision services as an additional scientifically proven biomedical strategy to prevent HIV
acquisition.
3. Treatment of positives
The idea to use antiretrovirals to prevent the acquisition and transmission of the Human
Immunodeficiency virus was tested early in the 90’s after animal models of retroviral infection
demonstrated that zidovudine could prevent or alter the course of maternally transmitted HIV
infection [30 – 33]. The results of this initial US Pediatric AIDS Clinical Trials Group Protocol
(PACTG) 076 clinical trial were announced in 1994, which showed that giving pregnant women
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infected with HIV oral zidovudine from 14 weeks, intravenously at labor and delivery, and
followed by six weeks of zidovudine prophylaxis to their newborns, could reduce transmission
by 67.5% (95 percent confidence interval, 40.7 to 82.1 percent) [30]. Since this pivotal study
proved the concept that antiretrovirals could be use to prevent HIV infection, significant
progress has been accomplished in the prevention of mother to child transmission, to the point
that current transmission rates are estimated at less than 2 percent with the use of triple
antiretroviral drugs during pregnancy. [34, 35], Figure 2. Despite these major advances in the
prevention of mother to child transmission of HIV-1, it was not until several years later that
these ideas were extrapolated to the prevention of sexual transmission of HIV-1. A central idea
was that the quantity of HIV-1 in plasma was a primary determinant of the risk of HIV-1
transmission [36]. By then it was already clear that antiretroviral therapy could reduce plasma
HIV-1 to undetectable concentrations within 6 months of initiation in most patients [37, 38]
and seminal and cervicovaginal HIV-1 concentrations could also be reduced to undetectable
levels in most people on ART [39 – 41]. A meta-analyses of data from five studies reported
only five cases of HIV-1 transmission from patients receiving antiretroviral therapy to sexual
partners during 1098 person-years of follow up, which is consistent with an infection rate of
0.19 – 1.09 per 100 person-years [42]. Additional evidence was obtained from a pos-hoc analysis
of the Partners in Prevention HSV/HIV Transmission study of acyclovir HSV-2 suppressive
therapy versus placebo [43]. In this analysis of almost 3,400 HIV-1 serodiscordant heterosexual
couples from seven African countries, ART use by the infected person was accompanied by a
92% reduction in the risk of HIV-1 transmission to their partner. Several other observational
and some ecological studies added to the evidence and set the need for a randomized study
to test the hypothesis if index individuals taking ART are less likely to transmit HIV infection
than individuals not on ART. In 2007 the HIV Prevention Trials Network (HPTN) started to
enroll participants in a multi-continent, randomized, controlled trial, called HPTN 052, to
compare early versus delayed antiretroviral therapy for patients with HIV-1 infection who had
CD4 counts between 350 and 550 cells per cubic millimeter and who were in a stable hetero‐
sexual relationship with a partner who was not infected [44]. A total of 1763 HIV-1 serodis‐
cordant couples were enrolled (886 couples were randomly assigned to the early therapy group
and 877 to the delayed-therapy group). The study was slated to end in 2015, but an interim
data review on April 26 2011, by an independent data and safety monitoring board (DSMB)
found that of the total 28 cases of HIV infection among the previously uninfected partners,
only one case occurred among those couples where the HIV-infected partner began immediate
antiretroviral therapy. The DSMB, therefore, called for immediate public release of the study's
findings on the basis of data collection through February 21, 2011. At that time, 90% of couples
remained enrolled in the study, with a median follow up of 1.7 years. This study demonstrated
the power of early antiretroviral treatment (ART) for almost completely preventing onward
sexual HIV transmission in the clinical trial setting. This study offered proof of the concept
that reduction of viral load through treatment could prevent HIV transmission, a concept that
has served as the foundation for multiple modeling studies on treatment-as-prevention and
one which was already held to be true by many. The data are incontrovertible, and although
they resolve the question of whether this approach can prevent HIV transmission, they also
lead to a more fully informed discussion of how ART might actually be used to prevent
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transmission in communities. The magnitude of protection against HIV infection demonstrat‐
ed in HPTN 052 has made the successful strategy of the clinical trial a key component of public
health policies recently discussed by federal officials and others saying that achieving an end
to the HIV/AIDS pandemic is now feasible with additional research and implementation
efforts. Given the profound implications of HPTN 052's for the future response to the AIDS
epidemic, the journal Science choose this study as its Breakthrough of the Year [45].
In summary, in 2011 it was scientifically demonstrated that treating individuals with HIV
infection will prevent the transmission of HIV infection. However, the use of this strategy to
the population level it is still not ready to fully achieve its potential because there are resource
constraints and logistical hurdles, that limit its implementation.
Figure 2. AIDS Diagnoses among perinatally infected persons, 1985-2010. United States and 6 U.S. dependent areas.
This slide from the CDC presents trends from 1985 through 2010 in the estimated numbers of
AIDS diagnoses among persons who were perinatally infected in the U.S. The blue line shows
the annual numbers of perinatally infected children who were diagnosed with AIDS when
they were less than 13 years of age; the pink line shows the annual numbers of persons who
were infected with HIV perinatally and were diagnosed with AIDS at the age of 13 or older.
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This graphic provides evidence of the impact at the population of an effective bio-medical
intervention to prevent HIV infection.
4. Pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) involves the use of antiretroviral medications by HIV
negative individuals before exposure to the HIV virus, to prevent HIV acquisition. The
principle behind the use of antiretrovirals (ART) to prevent sexually acquisition of HIV lies on
the success of HIV prevention in mother to Child transmission (PMTCT) and accidental
exposure in healthcare workers. Early in the HIV epidemics, two large prevention trials (HIV
Prevention Network Trial, HPTN 076 and HIVNET 012) showed that providing ART to infants
born to HIV positive mothers significantly decreased the rates of HIV infection in newborns
[30,46]. This is one of the greatest accomplishments in the field of HIV prevention, has been
incorporated to PMTCT guidelines, and provided a starting ground for PrEP [30,46, 47]. In the
area of health care related exposure to HIV, primarily needle sticks, the use of ART by the
negative individual during the weeks after exposure reduces HIV acquisition by 80% [48, 49].
Following the human studies assessing PMTCT and prevention in the healthcare setting,
animal studies to address PrEP demostrated that the administration of ART to macaque
monkeys exposed to HIV prevented HIV infection [50,51]. All this data provided basis for
designing clinical trials to test PrEP in humans.
In recent years, tremendous advances in the field of PrEP in individuals at risk for HIV
acquisition have led to landmark large randomized controlled studies using oral or topical
agents. Results of the initial major studies addressing PrEP were somehow controversial, but
recent data provides evidence that PrEP is an effective and safe alternative to prevent HIV
infection.
A major benefit of PrEP is its use by the individual at risk without involvement of sexual
partners. Men who have sex with men (MSM) and women are especially vulnerable to HIV
infection due to cultural, social and biological factors. Stigma associated with homosexuality,
gender disparities, inability for women to negotiate condom use and fidelity, as well as
frangibility of vaginal and rectal mucosa, predispose these populations to HIV infection and
make them ideal candidates for such preventive method. PrEP is therefore emerging as a new
powerful prevention method of especial importance in those populations at higher risk.
To date, most studies regarding PrEP have focused on two main modes of delivery: oral agents
or topical microbidides. The two delivery modes will be presented separate in this chapter.
Other forms of delivery such as subcutaneous or vaginal implants are under investigation and
will be briefly mentioned.
While some studies addressing PrEP yielded important and relevant results, other studies are
still undergoing and some are in the early stages of development. PrEP is therefore an evolving
area in the field of HIV prevention and emerging data is likely to change the way we prevent
sexually acquired HIV infection in the near future.
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Table 1 summarizes the results of clinical trials on oral and topical agents addressing PrEP.
Study name Sponsor Country Participants Design Results
iPREX (Grant 2010) NIAID
Gates
Foundation
South America
Thailand
USA
2,499 MSM FTC/TDF vs
placebo
42% reduction
(CI=6-60)
TDF2 (Thigpen 2012) CDC
NIH
Bostwana 1,219 heterosexual
men and women
FTC/TDF vs
placebo
62% reduction
(CI=21-83)
Partners PrEP (Baeten
2012)
Gates
Foundation
Sub Saharan African
countries
4,758
serodiscordant
couples
TDF vs placebo
FTC/TDF vs
placebo
TDF: 76%
reduction
(CI=42-81)
FTC/TDF: 75%
reduction (55-87)
FemPrEP (van Damme
2012)
US Agency for
International
Development
Kenia, Tanzania
South Africa
2,210 women FTC/TDF vs
placebo
Study discontinued
due to futility
(2011)
VOICE Microbicides
Trial Network
NIH
South Africa
Uganda, Zambia
Zimbabwe
5,000 women TDF vs placebo
FTC vs placebo
TDF gel vs placebo
TDF oral and gel
discontinued due
to futility (2011)
FTC/TDF ongoing
CAPRISA (Abdoul
Karim 2010)
Multiple
agencies
South Africa 1,341 women TDF gel vs placebo 39% reduction
Table 1. Summary of randomized controlled studies addressing the use of PrEP to prevent sexually transmitted HIV
infection.
4.1. PrEP using oral agents to prevent HIV infection in MSM and heterosexual men and
women
The oral agents evaluated or under evaluation for PrEP include anti HIV drugs currently
approved for treatment of HIV infection. Such drugs are tenofovir (TDF) and a combination
of emtricitabine/tenofovir FTC/ TDF.
Tenofovir is a nucleoside analog approved in combination with other ART for the treatment
of HIV infection. As a nucleoside analog, the mechanism of action of TDF is to blocking HIV
reverse transcriptase, which prevents HIV virus from replicating. In HIV infected individuals,
as a result, TDF lowers HIV viral load in the blood. Tenofovir is a drug that achieves good
drug levels in plasma as well as in female lower genital tract mucosa and rectal mucosa [52].
TDF is used orally and once a day, and is normally well tolerated, but as most drugs, could
have potential side effects. The most common side effects of TDF are gastrointestinal (nausea
and vomiting), rash or headaches, and occur in about 10% of the patients. The most serious
risk factors of TDF are acute liver and kidney toxicity. Chronic risk factors of TDF, relevant to
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the chronic use of TDF for PrEP, include decline in kidney function and decrease in bone
density [52].
Emtricitabine/tenofovir is a combination of nucleoside analogs approved for treatment of HIV.
FTC/TDF is formulated as single day pill and is taken in combination with other agents for the
treatment of HIV infection. Orally administered emtricitabine achieves good levels in plasma,
lower female genital tract, and especially in the rectum making this combination a promise for
PrEP [52]. The combination of FTC/TDF can cause those side effects listed above as well as
those associated with FTC. Emtricitabine common side effects include nausea, vomiting,
headaches, rash, abdominal pain, dizziness or abnormal dreams and occur in about 10% of the
cases. Emtricitabine can also be associated with fatal lactic acidosis, liver or kidney toxicity.
4.1.1. Studies addressing oral PrEP
Five studies have evaluated the use of oral agents to prevent HIV infection and will be
described in this section. One study included only MSM (iPrEX), 2 included men and women
(TDF2, PIP), and 2 included exclusively women (FEM-PrEP and VOICE). Two of these studies
have validated the use of PrEP for HIV prevention, two have been prematurely stopped due
to futility, and others are undergoing. Important to say is that all of these studies have
addressed the use of PrEP in combination with intensive safer sex practices counseling.
4.1.1.1. iPREX (pre exposure prophylaxis initiative)
iPREX was a randomized controlled study to evaluate the efficacy in reduction of new HIV
infections using a daily tablet of fixed dose of FTC/TDF when compared to placebo. iPREX
was funded by the National Institute of Allergy and Infectious Diseases and by the Bill and
Melinda Gates Foundation. The study included 2499 young high-risk MSM in South America,
Thailand and the US. The preliminary results of this study were released in 2010 and the study
was the landmark for the use of oral PrEP. Results suggested for the first time that oral ART
in combination with safe sex and condom use counseling could be used to reduce new HIV
infections in MSM. The use of oral FTC/TDF was associated with a 42% reduction in HIV
acquisition over 3 years (CI: 6%-60%). The study also analyzed the results according to self-
reported adherence and reveal the importance of adhere to the prescribed drug. The incidence
of new HIV cases was reduced to 68% when adherence was high (more than 90% of pills taken),
to 50% if adherence was between 50% and 90%, and to 32% if adherence was low (less than
50%). In order to clarify if detectable drug levels were associated with protection against HIV
infection a case control design was used to compare rates of infection in individuals with
detectable blood levels with those without detectable levels. A relative risk reduction of 92%
(CI: 40%-99%) in individuals with detectable study drug levels was found. This finding
provided evidence that protection was directly related with drug levels, an indirect measure‐
ment of adherence. In addition, this study showed that FTC/TDF had a good safety profile
with minimal gastrointestinal side effects. A minimal decrease in bone density in individuals
taking the drug was also observed. Among the individuals that seroconvert, most of them were
in the process of HIV seroconversion at enrollment and some developed a virus with resistant
mutations. This finding reinforced the importance of excluding HIV infection when using FTC/
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TDF for PrEP. The study results were published in the New England Journal of Medicine in
2010 [53]
4.1.1.2. TDF2
TDF2 was a randomized controlled study to evaluate the efficacy to reduce new HIV infection
of a daily fixed dose of an oral combination pill of TDF/FTC when compared to placebo. This
study was funded by the Centers for Disease Control and Prevention (CDC) and the division
of AIDS at the National Institutes of Health. The study was conducted in Bostwana and
included 1219 males and females, unmarried adults. This study had high rates of loss of follow
up (30%) and due to low retention, enrollment was prematurely stopped and study closed.
Enrolled participants were followed as planned and the last participant was followed until
2011. The results offered 62% (CI: 21%-83%) protection against HIV infection overall. This
study also evaluated drug levels in individuals receiving the drug and revealed that plasma
concentration were lower among the participants who seroconverted to HIV. Reported
adherence was high and similar in the two groups (above 80%), although detectable drug levels
in the drug arm suggested that adherence was lower that reported. Risky sexual behaviors
were similar and did not change in the two groups during the study. Among the participants
receiving the study drugs, there was and increase number of gastrointestinal side effects
(nausea and vomiting) and dizziness as well as a significant decline in bone density. One
participant was enrolled with unrecognized acute HIV infection and developed a resistant
virus [54].
4.1.1.3. Partners PrEP (partners in prevention)
Partners in Prevention study is the largest trial evaluating PrEP in heterosexual discordant
couples. It is an ongoing study with 3 study arms: daily TDF, daily TDF/FTC, and placebo.
This study is supported by the Bill and Melinda Gates Foundation. The study enrolled 4758
serodiscordant couples in which the HIV infected partner was not eligible for ART according
to country guidelines. This study in being conducted in sub Saharan Africa (Bostwana, Kenya,
Rwanda, South Africa, Tanzania, Uganda and Zambia). Extensive counseling in safe sex and
condom use was additionally provided to enrolled participants. TDF conferred a 67% (CI:
44%-81%) and FTC/TDF a 75% (CI: 55%-87%) reduction in new HIV infections. The difference
in rates of HIV seroconversion among the two treatment groups was not statistically different.
In July 2011 the DSMB recommended that the placebo group discontinued since the prede‐
termined criteria for stopping had already been made and a benefit in the treatment arms was
achieved [55]. The study results followed iPREX in supporting the use of PrEP in high risk
individuals.
4.1.1.4. FEM-PrEP
The  FEM-PrEP  study  was  a  randomized  controlled  trial  that  included  women  in  sub
Saharan  Africa  (Kenya,  South  Africa  and  Tanzania).  This  study  was  supported  by  US
Agency  for  International  Development.  Women were  randomized to  receive  either  oral
daily FTC/TDF or placebo. This study evaluated 2120 women and was the first one designed
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to  address the effectiveness and safety of  PrEP by gender.  Incidence of  new HIV infec‐
tions was 4.7% person-years in the treatment group and 5% person-years in the placebo
group and this different was not statistically significant. This study was the first large study
discontinued  based  on  recommendations  from  the  Data  Safety  Monitoring  Board  after
interim results  were unable to demonstrate efficacy of  PrEP.  In April  of  2011 the study
was stopped. As in prior studies, gastrointestinal side effects occurred more commonly in
the  treatment  arm (nausea,  vomiting and elevation of  ALT)  as  well  as  renal  laboratory
abnormalities. Despite extensive counseling on adherence, less than 40% of the women in
the treatment arm enrolled in the study had detectable drug levels raising once again the
importance of adherence to the prescribed regimen, perhaps lower in women [56].
4.1.1.5. VOICE (vaginal and oral interventions to control the epidemic)
VOICE is the largest clinical trial being conducted evaluating efficacy of PrEP in women. The
study is sponsored by the Microbicide Trials Network and the National Institutes of Health.
It enrolled over 5000 women in South Africa, Uganda, Zambia and Zimbabwe. Women were
randomized to 3 arms: daily oral TDF, daily oral TDF/FTC, or topical TDF. Results of this trial
resulted in the discontinuation of the oral TDF arm in September 2011 and the topical TDF arm
in November 2011 because of inability to demonstrate efficacy. The topical arm of the study
will be discussed under the microbicide section below and results of the TDF/FTC arm are
expected to be reported in 2013 [57].
4.1.1.6. Bangkok TDF trial
The Bangkok tenofovir study is an ongoing trial evaluating the efficacy of oral TDF in male
injection drug users receiving direct observation therapy. Enrollment for this study is complete
but no results are available at the time of this publication.
Studies addressing oral PrEP have yielded conflicting results and although the use of oral PrEP
appears to be beneficial in high risk MSM, the use in women still is under debate. Partners
PrEP, TDF2 and iPrEx provided a proof of concepts for the use of oral antiretrovirals for HIV
prevention. However, the results from VOICE and Fem-PrEP and other ongoing studies will
provide further information on the efficacy and safety of oral PrEP, especially in women.
Efficacy of PrEP seems to be directly related to adherence, and detectable blood levels is a
better marker of protection than self-reported adherence or pill count. Although in most
studies, adherence measured by self reporting or by pill count was high, detectable blood drug
levels were found only in 50% of participants in the treatment arm of iPREX [53].
The highest levels of adherence were reported in Partner PrEP, where serodiscordant couples
were enrolled and received extensive counseling. Tenofovir was detected in over 80% of
participants in the treatment group and PrEP reduced by 70% new HIV infections. The results
of Partner PrEP suggest that partner involvement is important, especially when addressing
HIV prevention in women [58,59].
In regards to decrease efficacy of PrEP in women the question of availability of drug at the
exposure site has been raised. However, high drug levels are found in cervicovaginal lavages,
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and even higher than in plasma or rectal mucosa, what would dispute this hypothesis [52,60].
Another possibility is a decrease of drug levels in women receiving hormonal contraceptives
and it is under evaluation by the study team.
Nevertheless, the possibility of low efficacy of oral PrEP in women suggest that microbicides
or other delivery methods may be a better option in this population.
Following the positive results of daily ART use for HIV prevention, especially in MSM, newer
studies are undergoing to evaluate the use of intermittent PrEP. These intermittent regimens
could be more feasible in certain setting such as in non stable relationships. A large study in
Kenia (ADAPT, Alternative Dosing to Augment PrEP Pill-Taking) is evaluating the safety and
adherence to daily oral TDF/FTC versus intermittent TDF/FTC (Monday, Friday and within 2
hours after sex) or placebo. Another study (HPTN 067) is a study including MSM and heter‐
osexual women aiming to identify dosing regiments in people at high risk for HIV infection.
Preliminary data demonstrated that although adherence may be decreased in intermittent
dosing, it may still be appropriate for PrEP.
4.1.2. Potential problems associated with oral PrEP
In July 2012, and based on the results of the mentioned trials, especially iPREX and Partners
PrEP, the United States Food and Drug administration (US FDA) approved the use of daily
TDF/FTC or Truvada® for prevention of sexually acquired HIV in individuals at risk for HIV
infection. However, even if approval was granted, serious concerns have been raised by experts
in the field of HIV prevention. The issues that need to be addressed before recommending
PrEP as a generalized HIV prevention strategy are: development of drug resistance viruses,
long term side effects, increase in sexual risk behaviors, cost, and incorporating PrEP as part
of primary care prevention.
4.1.2.1. Development of drug resistant viruses
Development of drug resistance was identified in some of the participants who seroconvert in
the mentioned studies but in most cases, occurred in individuals that enrolled with a new non
identified HIV infection. Addressing this potential problem is difficult, since individuals at
risk may have an early infection missed by routine antibody testing and routine viral load may
not be easily available in high risk settings.
4.1.2.2. Long term side toxicity
As both TDF and FTC have potential serious long term side effects, it is important to determine
if long use of FTC/TDF in HIV negative individuals will increase the risk of kidney failure or
osteoporosis. In order to evaluate long term side effects, long term follow up is necessary to
address if decline in renal function or bone density are clinically significant. However, as in
HIV positive individuals using those agents, side effects may take many years to develop.
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4.1.2.3. Increased of high risk sexual behavior
In regards to increase of risky sexual risk behaviors, both iPREX and Partners PrEP revealed
that all participants increased condom use, decrease number in sexual partners, unprotect‐
ed anal intercourse,  and reduced rates for syphilis.  This was likely due to the extensive
counseling that both drug and placebo groups received and sustainability of sexual risk
behavior needs to be further examined.
4.1.2.4. Cost
The cost of providing PrEP to individuals at risk is of course under great debate due to both
economical and ethical issues. ART are expensive medications and not available for all HIV
infected patients in need for their own health. PrEP is an expensive approach and cost
effectiveness will need to be justified prior to generalization to the population at risk. A cost-
effectiveness analysis of PrEP for HIV prevention in MSM published in 2012 in Annals of
Internal Medicine revealed that although PrEP could have an important impact in the HIV
epidemics, it will be an extremely expensive approach [63]. In a modeling analysis, Juusola
recently showed that providing PrEp to all high-risk MSM for 20 years will cost $75 billion in
health care related cost, a non-insignificant amount [61]. An ethical concern is whether
providing them to those HIV uninfected individuals will interfere with the treatment of HIV
infected patient in need for treatment, especially in poor resource settings.
4.1.3. Feasibility of generalizing the use of oral PrEP to the population at risk.
The use of PrEP includes identification of high risk individuals, extensive risk counseling,
provision of a drug and follow up risk assessments, HIV and laboratory tests. If PrEp is
incorporated as part of primary care prevention activities, the primary care physician will need
to become familiar with drugs normally prescribed for highly specialized physicians and will
need to be aware of new research data and changes in the recommendations as they become
available [63].
As summary, oral PrEP has demonstrated efficacy in certain populations at risk for HIV
infection, especially in MSM. Studies assessing acceptability, long term efficacy, toxicity, risk
of HIV resistance, cost and use in women are needed before including oral PrEP as part of HIV
prevention tools in the population at risk.
4.2. Microbicides to prevent HIV infection in women and MSM
Women are more vulnerable than men to acquire HIV during sex due to biological factors as
well as difficulties in negotiating barrier methods and fidelity. Women can rarely negotiate
condom use or faithfulness with their sexual partners and could greatly benefit of controlling
their own risk of HIV infection without involvement of male partners. Studies addressing oral
PrEP suggested lower efficacy of oral agents in women, which make microbicides an attractive
alternative for HIV prevention in women at risk.
Microbicides are topical products applied to the rectum or the vagina to prevent HIV infection
in HIV negative individuals. Research on microbicides has included primarily women but
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studies addressing several rectal formulations in MSM are currently undergoing. Unfortu‐
nately, results on microbicide research have been conflicting and further research is needed.
Topical vaginally applied TDF showed promising results in the CAPRISA trial. However, other
agents have not been efficacious and research in this area is ongoing.
In order for a microbicide to be successful it must fulfill the following characteristics: be
biologically active, safe, and acceptable by the individual at risk. The principals mechanisms
of action evaluated in microbide development are: buffer agents, surfactants, blockers and
antiretrovirals.
4.2.1. Buffers
Buffers are supplements to the natural immune defenses of the vagina. Buffers maintain the
vaginal pH favoring the persistence of the naturally protective vaginal lactobacilli. Alterations
of the vaginal pH due to exposure to semen or vaginal infections such as bacterial vaginosis
damage the vaginal microbiota and facilitate HIV infection. Buffergel ®, a buffer designed to
maintain vaginal pH was tested in animals and in a phase III effectiveness trial; but unfortu‐
nately, did not prevent new HIV infections [63].
4.2.2. Surfactants
Surfactants act by inactivating infectious agents. Noxynol-9, a wide available microbicide with
known activity against several infectious agents has been tested in multiple forms (film, sponge
and gel) and was not effective in preventing new HIV infections [64]. SAVVY® (C31G) was a
surfactant in a gel form tested in Ghana and Nigeria between 2004-2006 and not found to be
effective [65]. Surfactants are no longer being considered as potential agents for microbicide
use.
4.2.3. Blockers
Blockers inhibit the fusion of the HIV virus to the cell membrane. Four compounds in this
category have been tested to date: PRO2000®, Carrguard®, cellulose sulfate and dextrin 2-
sulfate and have not demonstrated activity in clinical trials [66].
4.2.4. Drugs with anti HIV activity
Antiretroviral agents act by inhibiting the HIV replication cycle in the vaginal mucosa have
been tested in two major clinical trials (CAPRISA and VOICE). Other agents acting as co-
receptor blockers binding to chemokine co-receptors such as VVR5 or CxCR4 are also under
investigation.
4.2.4.1. CAPRISA
The landmark study suggesting that the potential of microbicides as HIV prevention tools
is  CAPRISA,  a  two-arm randomized double  blind placebo controlled trial  conducted in
South Africa between 2007 and 2010. The study evaluated the efficacy in HIV reduction of
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a coitally (before and after sex) related application of TDF vaginal gel when compared to
placebo. 1341 women were enrolled. The incidence of HIV infections in the tenofovir arm
was 5.6 (CI: 4.0-7.7) per 100 women-years and 9.1 (CI: 6.9-11.7) in the placebo arm. (IRR:
0.61;  CI:0.4-0.94,p=0.017).  Tenofovir  gel  reduced  HIV acquisition  by  an  estimate  of  39%
overall  and by 54% in women with high adherence to  the gel.  This  study did not  find
major side effects associated with the use of TDF and no TDF resistant virus were found
in women who seroconverted. The results of this study were released in the Internation‐
al AIDS conference in Vienna in 2010 and provided a potential armamentum for women
unable to negotiate fidelity and condom use.  Caprisa also provided a reduction in HSV
acquisition [67].
4.2.4.2. VOICE
VOICE as described in the oral PrEP section included one arm evaluating daily use of vaginal
TDF gel. The gel arm enrolled approximately 1000 women. In September of 2011 this arm was
discontinued as a recommendation from the DSMB due to no efficacy. No safety issues were
identified [68]. In order to clarify if the differences between CAPRISA (39% reduction on new
HIV infections) was found and VOICE (no effect of TDF gel), a new study will replicate
CAPRISA (FACTS 001) and its results will help to clarify if TDF gel is useful and can be
incorporated to the field of HIV prevention.
4.2.5. Agents under development
4.2.5.1. Vaginal rings
The use of vaginal rings for prevention of HIV acquisition is under evaluation in several
studies. Vaginal rings with antivirals could potentially be used in combination with contra‐
ceptives, and will release antiviral agent long term and independent of sexual intercourse.
Dapivirine (TMC120) vaginal ring is currently evaluated under phase III studies as ASPIRE –
A Study to Prevent Infection with a Ring for Extended study [69]. A combination of Dapivirine
and Maraviroc is currently undergoing a phase 1 safety and pharmacokinetic study [70]. Other
vaginal rings with maraviroc alone or in combination with tenofovir are also being developed.
4.2.5.2. Long acting injectables
The use of a long acting injectable agent that will provide protection for 3-9 months is a
potential method that will increase adherence. Rilpivirine is under development for this
purpose [71].
PrEP using oral or topical agents is a promising strategy in the field of HIV prevention.
However, as single intervention may not be successful in controlling the HIV epidemics
and the results obtained in controlled clinical trials are unlikely to persist overtime. The
CDC recently published interim guidance for clinicians considering the use of PrEP for the
prevention of HIV infection in heterosexually active adults [72]. This report addresses the
remaining gap in knowledge regarding PrEP but provides a comprehensive evaluation of
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the  available  data  and  guidance  to  health  care  providers  regarding  the  use  of  PrEP.
However, HIV prevention guidelines are under development and 30 years of the history
of  HIV  have  shown  the  scientific  community  that  a  single  intervention  is  unlikely  to
succeed.
In summary, the science of HIV prevention has seen significant progress in recent years. After
decades of frustration and lagging behind the spectacular progress brought up in the control
of HIV disease by the use of antiretrovirals, the field of biomedical prevention of HIV has been
revolutionized and energized by the scientific evidence produced in the last few years that
supports the use of the four strategies discussed above: adult male circumcision, treatment of
HIV infected people, pre-exposure prophylaxis and microbicides (Figure 3). However,
although the foundations for successful HIV prevention programs are being laid out, there are
still significant challenges ahead that will need to be solved before all these strategies can be
fully scaled up, combined and delivered to the at risk individuals and communities. The field
is also confident that the still elusive vaccine to prevent HIV infection can be unveiled in a not
distant future.
Figure 3 lists currently proven biomedical interventions that prevent sexually transmitted HIV
infection by gender.
Figure 3. Interventions to Prevent Sexually Transmited HIV Infection by Gender
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